SGMO vs. MYGN, ZBIO, EBS, LXRX, RIGL, CBIO, XOMA, VNDA, VSTM, and CDXS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Crescent Biopharma (CBIO), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Codexis (CDXS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs. Its Competitors
Myriad Genetics (NASDAQ:MYGN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 2.4% of Myriad Genetics shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Myriad Genetics has a net margin of -12.20% compared to Sangamo Therapeutics' net margin of -124.61%. Myriad Genetics' return on equity of -4.95% beat Sangamo Therapeutics' return on equity.
Sangamo Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500.
Myriad Genetics currently has a consensus target price of $14.38, indicating a potential upside of 156.87%. Sangamo Therapeutics has a consensus target price of $4.50, indicating a potential upside of 739.55%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Myriad Genetics.
In the previous week, Sangamo Therapeutics had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 2 mentions for Sangamo Therapeutics and 1 mentions for Myriad Genetics. Sangamo Therapeutics' average media sentiment score of 0.27 beat Myriad Genetics' score of 0.00 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.
Summary
Sangamo Therapeutics beats Myriad Genetics on 9 of the 15 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 7/4/2025 by MarketBeat.com Staff
Free SGMO Stock Alerts